Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating income | -$35.3M | -$68.2M | -$98.1M |
| Net income | -$32.6M | -$61.9M | -$87.0M |
| EPS (diluted) | -$31.96 | -$5.82 | -$2.38 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$32.0M | -$54.7M | -$79.9M |
| Capital expenditures | $129K | $874K | $1.93M |
| Free cash flow | -$32.1M | -$55.6M | -$81.9M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $30.5M | $49.4M | $75.3M |
| Total assets | $84.2M | $269M | $385M |
| Total liabilities | $4.29M | $11.1M | $15.9M |
| Shareholders' equity | -$72.5M | $257M | $369M |
| Retained earnings | -$75.6M | -$138M | -$224M |
| Shares (wtd avg diluted) | 1.02M | 10.6M | 36.5M |
Every figure is extracted from MBX Biosciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.